

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

SCIELE PHARMA, INC. <i>et al.</i> ,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 09-037 (RBK) (JS)
	)	(CONSOLIDATED)
LUPIN LTD., <i>et al.</i> ,	)	
	)	
Defendants.	)	
	)	
<hr/> SHIONOGI, INC., <i>et al.</i> ,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 10-135 (RBK) (JS)
	)	
MYLAN, INC., <i>et al.</i> ,	)	
	)	
Defendants.	)	

**JOINT STIPULATION REGARDING BRIEFING SCHEDULE**

IT IS HEREBY STIPULATED AND AGREED, by and among the undersigned counsel for Plaintiffs Sciele Pharma, Inc., n/k/a Shionogi, Inc., Andrx Corporation, Andrx Pharmaceuticals, Inc. (n/k/a Watson Laboratories, Inc.-Florida), Andrx Pharmaceuticals, L.L.C., Andrx Pharmaceuticals, (NJ), Inc., Andrx EU, Ltd., and Andrx Labs, L.L.C. (collectively “Plaintiffs”) and Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively “Lupin”) that the briefing schedule for (a) Lupin’s Motion for a Protective Order Concerning Its Highly Sensitive Commercial Information Involving Commercial Relationships and Settlement Negotiations (“Lupin’s Protective Order Motion”), (b) Lupin’s Motion to Bifurcate Liability and Damages and to Stay Damages Discovery (“Lupin’s Bifurcation Motion”), and (c) Plaintiffs’ Motion for a Protective Order Regarding Defendant Lupin’s Notices of Depositions to Shionogi

and Andrx Pursuant to Fed. R. Civ. P. 30(b)(6) ("Plaintiffs' Protective Order Motion") shall be as follows:

1. Plaintiffs shall file their opposition brief to Lupin's Protective Order Motion by May 1, 2012.
2. Lupin shall file its reply brief in further support of its Protective Order Motion by May 7, 2012.
3. Plaintiffs shall file their opposition brief to Lupin's Bifurcation Motion by May 2, 2012.
4. Lupin shall file its reply brief in further support of its Bifurcation Motion by May 8, 2012.
5. Lupin shall file its opposition to Plaintiffs' Protective Order Motion by May 1, 2012.
6. Plaintiffs shall file their reply brief in further support of their Protective Order Motion by May 7, 2012.

Dated: May 1, 2012

RICHARDS, LAYTON & FINGER P.A.

*/s/ Steven J. Fineman*

---

Frederick L. Cottrell, III (#2555)  
Steven J. Fineman (#4025)  
One Rodney Square  
P.O. Box 551  
Wilmington, DE 19899  
(302) 651-7700  
cottrell@rlf.com  
fineman@rlf.com

*Attorneys for Andrx Corporation, Andrx  
Pharmaceuticals, Inc. (n/k/a Watson  
Laboratories, Inc.-florida), Andrx*

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

*/s/ Karen Jacobs Louden*

---

Jack B. Blumenfeld (#1014)  
Karen Jacobs Louden (#2881)  
Julia Heaney (#3052)  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899-1347  
(302) 658-9200  
jblumenfeld@mnat.com  
klouden@mnat.com  
jheaney@mnat.com

*Attorneys for Sciele Pharma, Inc.*

*Pharmaceuticals, L.L.C., Andrx Laboratories  
(NJ), Inc., Andrx EU Ltd. and Andrx Labs,  
L.L.C.*

OF COUNSEL:

Gary E. Hood  
POL SINELLI SHUGHART PC  
161 North Clark Street, Suite 4200  
Chicago, IL 60601-3316

Robyn H. Ast  
POL SINELLI SHUGHART PC  
100 South Fourth Street, Suite 1000  
St. Louis, MO 63102

OF COUNSEL:

David A. Manspeizer  
David B. Bassett  
Christopher R. Noyes  
David M. Burkoff  
Peter Shen  
WILMER CUTLER PICKERING HALE AND DORR LLP  
399 Park Avenue  
New York, NY 10022

Liza M. Walsh  
Rukhsanah Lighari  
Patrick J. Murphy  
CONNELL FOLEY LLP  
85 Livingston Avenue  
Roseland, NJ 07068

BAYARD, P.A.

*/s/ Stephen B. Brauerman*

---

Richard D. Kirk (#922)  
Stephen B. Brauerman (#4952)  
222 Delaware Avenue, Suite 900  
Wilmington, DE 19801  
(302) 655-5000  
rkirk@bayardlaw.com  
sbrauerman@bayardlaw.com


*Attorneys for Lupin Ltd. and Lupin  
Pharmaceuticals, Inc.*

OF COUNSEL:

Douglass C. Hochstetler  
KELLEY DRYE & WARREN LLP  
333 West Wacker Drive, 26<sup>th</sup> Floor  
Chicago, IL 60606

Beth D. Jacob  
Clifford Katz  
KELLEY DRYE & WARREN LLP  
101 Park Avenue  
New York, NY 10178

Karen A. Confoy  
Erica A. Helms  
STERNS & WEINROTH PC  
50 West State Street, Suite 1400  
Trenton, NJ 08607

So Ordered this 1st day  
of May, 2012  
  
JOEL SCHNEIDER, USMJ